ClinicalTrials.gg
RecruitingNCT07445971Updated Sep 10, 2026

A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.

A Phase 1 interventional study of MDX2301 and Normal Saline in COVID -19 and COVID-19 (Prevention), sponsored by ModeX Therapeutics, An OPKO Health Company. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by ModeX Therapeutics, An OPKO Health Company (part of OPKO Health, Inc.) · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,859 studies in COVID-19 with a site in United States — 119 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Planned enrollment
685th of 1,321
80 · median 91
Started
2026
with 21 others
Phase 1
178 of 1,859
10 open now
Primary completion
2027-09
later than 140 of 208 live
Registered
1,836th of 1,859
by date

Among the 1,859 studies in COVID-19 with a site in United States, this one is the 685th largest by planned enrollment of the 1,321 interventional ones that give a count, is one of 22 that started in 2026, is one of 178 in phase 1, reaches primary completion later than 140 of the 208 other live ones, and was the 1,836th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

Browse COVID-19 studies →

Open to participants now

119 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

113 more — sign in →

All 119 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 355 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 90 take children under 18; 134 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,859 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics, anti-drug antibodies, and neutralizing activity of MDX2301 administered by intravenous (IV), intramuscular (IM), or subcutaneous (SC) routes in healthy adults and adults at higher risk for severe COVID-19. Participants will receive single IV, IM, and SC doses of MDX2301 or placebo and a repeat IM or SC dose approximately 3 months apart of MDX2301 or placebo.

03

Conditions studied

  • COVID -19
  • COVID-19 (Prevention)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy Adults

  1. Participant is a healthy male or female, 18 to 64 years of age.
  2. Participant is in good health in the opinion of the investigator.

    Adults at Higher Risk for Developing Severe COVID-19:

  3. Participant is a male or female, 18 to 64 years of age.
  4. Participant is at higher risk for developing severe COVID-19, with 1 or more of the following risk factors:

    1. Asthma
    2. Diabetes
    3. Cerebrovascular disease, which affects blood flow to the brain.
    4. Chronic kidney disease
    5. Chronic lung disease
    6. Cardiac disease
    7. Chronic liver disease
    8. Cystic fibrosis
    9. clinically stable on antiretroviral therapy for at least 6 months prior to screening.
    10. Sickle cell disease or thalassemia
  5. Participant is clinically stable with no abnormalities.
  6. Participant has not been hospitalized within the 12 months prior to screening or is not expected to be hospitalized during the study due to underlying medical conditions.

    All Participants

  7. Female participants of must have a negative urine pregnancy test.
  8. Female participants of childbearing potential must agree to follow instructions for a highly effective method.
  9. Participant is able to understand and sign the form prior to undergoing any study procedures.
  10. Participant is willing and able to comply with scheduled visits and procedures.

Exclusion criteria

Exclusion Criteria:

Healthy Adults

  1. Participant has any chronic or significant medical condition that, in the opinion of the investigator, might compromise the participant's safety or interfere with evaluation of the study drug.
  2. Participant has evidence of active , , or infections at screening.

    Adults at Higher Risk for Severe COVID-19:

  3. Participant has any serious disease, condition, or disorder that, in the opinion of the investigator, might compromise the participant's safety or interfere with evaluation of the study drug or interpretation of study results, or may lead to hospitalization or death within the study period.
  4. Participant has evidence of active hepatitis B or hepatitis C infections at screening.

    All Participants

  5. Participant has abnormal vital signs, findings, or laboratory values at Screening or Day -1.
  6. Participant tests positive for SARS-CoV-2 infection at screening.
  7. Participant self-reports having COVID-19 or received COVID-19 antiviral for prophylaxis or treatment prior to Day 1.
  8. Participant has received a SARS-CoV-2 vaccine prior to dosing.
  9. Participant has received a monoclonal antibody (mAb) for SARS-CoV-2 or convalescent plasma for SARS-CoV-2 prior to Day 1.
  10. Participant has received or is expected to receive for the duration of the study immunoglobulin, blood-derived products, high-dose systemic , or other drugs within 6 months prior to Day 1.
  11. Participant is pregnant, breastfeeding, or seeking pregnancy while on the study.
  12. Participant with a known bleeding disorder that would prohibit the participant from receiving an IV infusion or IM or SC injection.
  13. Participant had major surgery within 30 days prior to Day 1.
  14. Participant has donated blood prior to screening.
  15. Participant has any skin condition and/or tattoo that may interfere with the evaluation of safety at the injection site.
  16. Participant has a history of alcoholism or illicit drug use prior to screening or a positive test for drugs of abuse at screening or on Day -1.
  17. Participant is a current smoker or user of other nicotine containing products on a daily basis.
  18. Participant has received an product within 30 days prior to Day 1.
  19. Participant has a known to any components of MDX2301, any of its or closely related compounds.

    For All Participants, Temporary Exclusions for Randomization on Day 1 if Remains within the Screening Window:

  20. Participant has any acute illness, within 3 days of Day 1.
  21. Participant has vital signs considered by the investigator to be clinically significant prior to study drug administration.
  22. Participant has had close contact with anyone confirmed to have SARS-CoV-2 infection within the 7 days prior to Day 1.
  23. Any acute drug therapy prescribed by a physician within 7 days prior to Day 1.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Single Dose Healthy Adults MDX2301

    Healthy Adults will receive a single dose of MDX2301 as intravenous infusion, intramuscular injection, or subcutaneous injection.

    Biological: MDX2301

  • Placebo comparator
    Single Dose Healthy Adults Placebo

    Healthy Adults will receive a single dose of placebo as intravenous infusion, intramuscular injection, or subcutaneous injection.

    Biological: Normal Saline

  • Experimental
    Repeat Dose Healthy Adults MDX2301

    Healthy Adults will receive a single dose of MDX2301 as intramuscular injection or subcutaneous injection and then receive a repeat dose of MDX2301, 3 months later as intramuscular injection or subcutaneous injection.

    Biological: MDX2301

  • Placebo comparator
    Repeat Dose Healthy Adults Placebo

    Healthy Adults will receive a single dose of placebo as intramuscular injection or subcutaneous injection and then receive a repeat dose of placebo 3 months later as intramuscular injection or subcutaneous injection.

    Biological: Normal Saline

  • Experimental
    Single-Dose Higher Risk Adults MDX2301

    Adults at higher risk for severe COVID-19 will receive a single dose of MDX2301 as intramuscular injection or subcutaneous injection.

    Biological: MDX2301

  • Placebo comparator
    Single-Dose Higher Risk Adults Placebo

    Adults at higher risk for severe COVID-19 will receive a single dose of placebo as intramuscular injection or subcutaneous injection.

    Biological: Normal Saline

Interventions

  • BiologicalMDX2301

    MDX2301 as intravenous infusion, intramuscular injection, or subcutaneous injection.

  • BiologicalNormal Saline

    Placebo as intravenous infusion, intramuscular injection, or subcutaneous injection.

  • BiologicalNormal Saline

    Placebo as intramuscular injection or subcutaneous injection.

  • BiologicalMDX2301

    MDX2301 as intramuscular injection or subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Incidence and severity of adverse events (AEs) and serious AEs (SAEs), including changes in clinical laboratory parameters.

    Time frame: Baseline until end of study, up to approximately 12 months

Secondary outcomes

  1. Measure of maximum serum concentration (Cmax) of MDX2301

    Characterize pharmacokinetic (PK) parameter Cmax after administration of MDX2301

    Time frame: 12 months

  2. Measure of time to maximum concentration (Tmax) of MDX2301

    Characterize pharmacokinetic (PK) parameter Tmax after administration of MDX2301

    Time frame: 12 months

  3. Measure of terminal half-life (t1/2) of MDX2301

    Characterize pharmacokinetic (PK) parameter t1/2 after administration of MDX2301.

    Time frame: 12 months

  4. Measure of area under the serum concentration-time curve (AUC) extrapolated to infinity of MDX2301

    Characterize pharmacokinetic (PK) parameters AUC after administration of MDX2301

    Time frame: 12 months

  5. Measure of volume of distribution (Vd) of MDX2301

    Characterize pharmacokinetic (PK) parameter Vd after administration of MDX2301.

    Time frame: 12 months

  6. Incidence of treatment-emergent anti-drug antibodies (ADA) of MDX-2301

    Quantification of ADAs after MDX2301 administration

    Time frame: 12 months

  7. Evaluation of serum virus neutralizing antibodies of MDX2301

    Measure of the level of serum virus neutralizing antibodies of MDX2301 against relevant SARS-CoV-2 variants.

    Time frame: 12 months

07

Study locations

2 of 2 sites recruiting
  • TrialMed Clinical Research Unit
    Las Vegas, Nevada 89113, United States
    Recruiting
    • ModeX Therapeutics · Contactinfo@modextx.com · +1 857-233-9936
    • Shawn Searle, MD · Principal investigator
  • TrialMed Clinical Research Unit
    Austin, Texas 78744, United States
    Recruiting
    • ModeX Therapeutics · Contactinfo@modextx.com · +1 857-233-9936
    • Kristie Miller, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Sep 2027, 18 months after the start.

Of 233 industry-sponsored phase 1 interventional studies under COVID-19, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's planned 18 months is above that.

Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2026
First posted
Mar 3, 2026
StartActual
Mar 24, 2026
Primary completionEst.
Sep 2027
CompletionEst.
Dec 2027
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07445971
Responsible party
Sponsor
First posted
Mar 3, 2026
Start date
Mar 24, 2026
Primary completion
Sep 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 10, 2026

Study contacts

ModeX Therapeutics, An OPKO Health Company
Contact
info@modextx.com
857-233-9936
Trial Med
principal investigator · TrialMed

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion